9.5426

2.29% 0.3726

Xilio Therapeutics Inc (XLO)

Overview News Price History Financials Discussions Forecast

Xilio Therapeutics Inc stock is traded at $9.5426, with a volume of 12,667. It is up +2.29% in the last 24 hours and up +5.63% over the past month. Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.

Previous Close:

$9.17

Open:

$9.07

24h Volume:

12,667

Relative Volume:

0.28

Market Cap:

$62.35M

Revenue:

$43.77M

Net Income/Loss:

$-35.04M

P/E Ratio:

-2.9343

EPS:

-3.2521

Net Cash Flow:

$-5.51M

1W Performance:

+1.96%

1M Performance:

+5.63%

6M Performance:

+20.31%

1Y Performance:

-5.50%

1-Day Range:

$9.07

$9.90

1-Week Range:

$8.6845

$9.90

52-Week Range:

$6.4652

$12.74

Xilio Therapeutics Inc Stock (XLO) Company Profile

Name

Xilio Therapeutics Inc

Sector

Healthcare (1089)

Industry

Biotechnology (604)

Phone

617-833-1027

Address

828 WINTER STREET, WALTHAM

Employee

Twitter

Next Earnings Date

2026-08-13

Latest SEC Filings

XLO's Discussions on Twitter

Compare XLO vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
XLO Xilio Therapeutics Inc	9.475	60.34M	43.77M	-35.04M	-5.51M	-3.2521
VRTX Vertex Pharmaceuticals Inc	515.31	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	806.34	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	992.59	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	215.54	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.30	39.31B	5.76B	514.49M	1.10B	4.4813

Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-06-25	Initiated	Leerink Partners	Outperform
Dec-21-22	Initiated	Chardan Capital Markets	Buy
Jan-10-22	Initiated	H.C. Wainwright	Buy
Nov-16-21	Initiated	Cowen	Outperform
Nov-16-21	Initiated	Guggenheim	Buy
Nov-16-21	Initiated	Morgan Stanley	Overweight
Nov-16-21	Initiated	Raymond James	Outperform

View All

Xilio Therapeutics Inc Stock (XLO) Latest News

07:27 AM

Weekly Recap: Xilio (XLO) Q2 revenue jump and FDA IND cleared for XTX501 - TradingView

07:27 AM

Aug 14, 2026

StemPoint group (XLO) discloses 9.5% Xilio Therapeutics stake via warrants - Stock Titan

Aug 14, 2026

Aug 13, 2026

Xilio Therapeutics earnings beat by $0.25, revenue topped estimates - Investing.com Canada

Aug 13, 2026

Aug 12, 2026

Xilio Therapeutics (NASDAQ:XLO) Announces Earnings Results, Beats Estimates By $0.26 EPS - MarketBeat

Aug 12, 2026

Xilio Therapeutics Releases Q2 2026 Financial Results - AlphaStreet

Aug 12, 2026

Xilio Therapeutics Q2 Results: Sales up 131% YoY to $18.7M - scanx.trade

Aug 12, 2026

Xilio Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Aug 12, 2026

Xilio Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 12, 2026

Form 8K Xilio Therapeutics Inc For: 12 August By Investing.com - Investing.com Nigeria

Aug 12, 2026

Xilio Therapeutics, Inc. 2Q 2026: Revenue $18.7M, EPS $(0.33) — 10-Q Summary - TradingView

Aug 12, 2026

Xilio Therapeutics reports Q2 2026: $18.7M collaboration revenue, $6.4M net loss, cash $136.0M - TradingView

Aug 12, 2026

Xilio Therapeutics (XLO) lifts collaboration revenue and trims net loss in 2026 - Stock Titan

Aug 12, 2026

Xilio Therapeutics Reports $18.7 Million Q2 Revenue and FDA Clearance for XTX501 - Quiver Quantitative

Aug 12, 2026

Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates - The Manila Times

Aug 12, 2026

Xilio Therapeutics Reports Second Quarter 2026 Financial Results And Provides Pipeline And Business Updates - TradingView

Aug 12, 2026

Xilio expects to dose cancer patients with XTX501 in H2 2026 - Stock Titan

Aug 12, 2026

Aug 11, 2026

Xilio Therapeutics (XLO) Holds Steady at $9.18 as Biotech Stock Consolidates Near SupportMomentum Factor - dars.gov.et

Aug 11, 2026

Aug 09, 2026